Brent Vaughan

CEO at Stealth TechBio

Speaker

I am passionate about building novel healthcare products and companies that leverage breakthrough technologies to address unmet medical needs. I enjoy integrating a deep understanding of innovative science and healthcare together with my experience with regulatory frameworks and commercialization to create visionary product-market-fit and first-in-class healthcare products and companies.

I have broad experience in company formation, transforming organizations and scaling high-performance teams to develop novel drugs, medical devices and healthcare platforms. My experience includes drug and device development in CNS, cardiometabolic diseases and oncology and, breakthrough products that leverage AI/ML and optogenetics.

As a CEO and company leader, I have successfully raised over $200M in series A, B and C rounds of equity funding and have been successful founding and scaling companies as well as leading transformational growth in more mature organizations. I have led the development of novel drug and medical device products from creation of foundational IP and IND-enabling and MVP product development, through completion of multiple successful clinical programs that resulted in 3 FDA Breakthrough designations, FDA approval of the first-in-category ML/AI based CNS diagnostic and, one of the leading Alzheimer’s Ph3/pivotal development programs.

My earlier career experience was in pharma and biotech commercialization, marketing, product and business development in established organizations including Lilly, Roche and Novartis and Nektar. I then pursued opportunities to combine this commercial perspective and product vision to build breakthrough healthcare products and companies leveraging new technologies.

I have multiple patents and patents pending in areas related to the application of AI/ML and optogenetics to diagnose and treat CNS conditions and often speak at thought-leader events in the US and Europe on CNS, Alzheimer’s and scaling innovative technology in healthcare.